Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1360131632
rs1360131632
STAT5A
0.040 GeneticVariation BEFREE Alternative strategies to specifically target T315I-BCR-ABL are needed for the treatment of CML patients harboring such a mutation. 29358661

2018
dbSNP: rs1360131632
rs1360131632
STAT5A
0.040 GeneticVariation BEFREE SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia. 28595903

2017
dbSNP: rs1360131632
rs1360131632
STAT5A
0.040 GeneticVariation BEFREE Leukemia cells escape BCR-ABL-targeted therapy by developing mutations, such as T315I, in the p210(BCR-ABL) fusion protein in Philadelphia chromosome-positive chronic myeloid leukemia (CML). 26846820

2016
dbSNP: rs1360131632
rs1360131632
STAT5A
0.040 GeneticVariation BEFREE IRDs represent a promising structural class for development of new therapeutics for wild type or T315I mutant Bcr-Abl-positive CML patients. 22387217

2012